MARKET

ETTX

ETTX

Entasis Therapeutics Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.06
+0.04
+0.80%
Opening 11:56 02/27 EST
OPEN
5.06
PREV CLOSE
5.02
HIGH
5.06
LOW
5.06
VOLUME
620
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
4.240
MARKET CAP
62.83M
P/E (TTM)
-1.7520
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ETTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ETTX stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.

EPS

ETTX News

More
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga · 01/16 12:22
  • Entasis Therapeutics Holdings Inc. (ETTX): Are Hedge Funds Right About This Stock?
  • Insider Monkey · 11/24/2019 18:56
  • Entasis Therapeutics Hldg Q3 EPS $(0.27) Up From $(20.33) YoY, Sales $7K
  • Benzinga · 11/14/2019 12:38
  • Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
  • GlobeNewswire · 11/14/2019 12:30

Industry

Pharmaceuticals
-1.12%
Pharmaceuticals & Medical Research
-1.29%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ETTX

Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant Gram-negative bacteria. Its lead product candidate ETX2514 and its other product candidate ETX0282 inhibits bacterial resistance, b-lactamase enzyme. Its pipeline includes ETX2514UL, ETX0282CPDp, Zoliflodacin, and non-beta (b)-lactam inhibitors of the penicillin-binding proteins (NBP) Program. ETX2514SUL is a fixed-dose combination of ETX2514 with sulbactam, as a novel IV antibiotic with broad spectrum b-lactamase coverage. Zoliflodacin as a single dose, oral antibiotic monotherapy. ETX0282CPDP is an oral fixed-dose combination of ETX0282 with cefpodoxime proxetil. The Company is developing a class of antibiotics with its NBP program in which it is designing molecules for optimal activity against the penicillin-binding proteins (PBP) enzymes.
More

Webull offers kinds of Entasis Therapeutics Holdings Inc stock information, including NASDAQ:ETTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ETTX stock news, and many more online research tools to help you make informed decisions.